Literature DB >> 16980946

Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.

Jared J Abbott1, Michele Erickson-Johnson, Xiaoke Wang, Antonio G Nascimento, Andre M Oliveira.   

Abstract

Dermatofibrosarcoma protuberans is a superficial low-grade sarcoma that rarely evolves into a high-grade fibrosarcoma. Dermatofibrosarcoma protuberans is genetically characterized by the unbalanced chromosomal t(17;22)(q21;q13), usually in the form of a supernumerary ring chromosome. The product of this chromosomal translocation is the chimeric gene COL1A1-PDGFB (collagen type I alpha I-platelet-derived growth factor beta), which is amplified at low levels in the ring chromosome. The aims of this study were to evaluate (1) whether genomic gains of this fusion gene occur during the clonal evolution of dermatofibrosarcoma protuberans into fibrosarcomatous dermatofibrosarcoma protuberans and (2) whether there is a difference between the number of genomic copies of COL1A1-PDGFB between classic dermatofibrosarcoma protuberans and dermatofibrosarcoma protuberans areas associated with fibrosarcomatous dermatofibrosarcoma protuberans. Eleven cases of fibrosarcomatous dermatofibrosarcoma protuberans with both dermatofibrosarcoma protuberans and fibrosarcomatous areas and 10 cases of classic dermatofibrosarcoma protuberans were studied. Genomic copies of COL1A1-PDGFB were evaluated by fluorescence in situ hybridization using a custom designed probe for the PDGFB locus on 4 mum thick paraffin-embedded tissue sections. Genomic gains of the COL1A1-PDGFB gene were observed in six (of 10) fibrosarcomatous dermatofibrosarcoma protuberans in the fibrosarcomatous areas when compared to the dermatofibrosarcoma protuberans areas of the same tumor (2-7 gene copies (median PDGFB copy gain, 2.8) versus 1-3 gene copies (median PDGFB copy gain, 1.7), respectively, P=0.004). Four fibrosarcomatous dermatofibrosarcoma protuberans did not show genomic gains of COL1A1-PDGFB fusion gene between the two areas. Essentially no difference in the copy number of COL1A1-PDGFB fusion gene was observed between dermatofibrosarcoma protuberans areas of classic dermatofibrosarcoma protuberans and dermatofibrosarcoma protuberans areas of fibrosarcomatous dermatofibrosarcoma protuberans (median PDGFB copy gain of 1.8 versus 1.7, respectively, P=0.36). Genomic gains of COL1A1-PDGFB fusion gene is possibly an oncogenic mechanism that is identified in the clonal evolution of a subset of dermatofibrosarcoma protuberans that evolves into fibrosarcomatous dermatofibrosarcoma protuberans. Since this finding was not observed in all cases of fibrosarcomatous dermatofibrosarcoma protuberans, other oncogenic mechanisms may be operating in this form of tumor progression. Copy number of COL1A1-PDGFB fusion gene in the classic dermatofibrosarcoma protuberans areas does not seem to be a major predisposing mechanism for fibrosarcomatous transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980946     DOI: 10.1038/modpathol.3800695

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

Review 1.  Do all lung adenocarcinomas follow a stepwise progression?

Authors:  Yasushi Yatabe; Alain C Borczuk; Charles A Powell
Journal:  Lung Cancer       Date:  2011-06-25       Impact factor: 5.705

2.  PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.

Authors:  Khadijeh Jahanseir; Deyin Xing; Patricia T Greipp; William R Sukov; Gary L Keeney; Brooke E Howitt; J Kenneth Schoolmeester
Journal:  Int J Gynecol Pathol       Date:  2018-11       Impact factor: 2.762

3.  CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Authors:  Grant Eilers; Jeffrey T Czaplinski; Mark Mayeda; Nacef Bahri; Derrick Tao; Meijun Zhu; Jason L Hornick; Neal I Lindeman; Ewa Sicinska; Andrew J Wagner; Jonathan A Fletcher; Adrian Mariño-Enriquez
Journal:  Mol Cancer Ther       Date:  2015-04-07       Impact factor: 6.261

4.  Fibrous hamartoma of infancy: a clinicopathologic study of 145 cases, including 2 with sarcomatous features.

Authors:  Alyaa Al-Ibraheemi; Anthony Martinez; Sharon W Weiss; Harry P Kozakewich; Antonio R Perez-Atayde; Henry Tran; David M Parham; William R Sukov; Karen J Fritchie; Andrew L Folpe
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Authors:  Elisabetta Pennacchioli; Giulio Tosti; Massimo Barberis; Tommaso M De Pas; Francesco Verrecchia; Claudia Menicanti; Alessandro Testori; Giovanni Mazzarol
Journal:  Clin Exp Metastasis       Date:  2012-06-15       Impact factor: 5.150

Review 6.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

7.  DNA copy gains of tumor-related genes in vestibular schwannoma.

Authors:  Luis Lassaletta; Miguel Torres-Martín; Jesús San-Román-Montero; Javier S Castresana; Javier Gavilán; Juan Antonio Rey
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-21       Impact factor: 2.503

Review 8.  Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck.

Authors:  Esther Baranov; Jason L Hornick
Journal:  Head Neck Pathol       Date:  2020-01-16

9.  PDGFB RNA in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans.

Authors:  Jeffrey M Cloutier; Grace Allard; Gregory R Bean; Jason L Hornick; Gregory W Charville
Journal:  Mod Pathol       Date:  2021-03-24       Impact factor: 7.842

10.  Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.

Authors:  Dennis A Wicherts; Frits van Coevorden; Houke M Klomp; Martine A van Huizum; J Martijn Kerst; Rick L M Haas; Hester H van Boven; J A van der Hage
Journal:  World J Surg Oncol       Date:  2013-03-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.